STABILITY INDICATING HIGH-PERFORMANCE THIN LAYER LIQUID CHROMATOGRAPHIC METHOD FOR EVEROLIMUS

MRINALINI C. DAMLE; PAYAL Y. KAITKAR

doi:10.22159/ijpps.2024v16i9.50799

Authors

MRINALINI C. DAMLE Head of Department, Quality Assurance, All India Shri Shivaji Memorial Society’s College of Pharmacy, Pune-411001, Maharashtra, India https://orcid.org/0000-0001-9595-5528
PAYAL Y. KAITKAR Master of Pharmacy, Department of Quality Assurance, All India Shri Shivaji Memorial Society’s College of Pharmacy, Pune-411001, Maharashtra, India https://orcid.org/0009-0008-4556-5474

DOI:

https://doi.org/10.22159/ijpps.2024v16i9.50799

Keywords:

Everolimus, HPTLC, LC-MS, Forced degradation, Stability indicating

Abstract

Objective: Developing and validating a stability-indicating method for everolimus by HPTLC and depiction of degradation product of in alkaline conditions by LC-MS.

Methods: The chromatographic separation was performed on aluminium plates pre-coated with silica gel 60 F₂₅₄ as the stationary phase using Toluene: Methanol: Ethyl Acetate (6:2:2v/v/v) as the mobile phase. The evaluation was carried out at 277 nm. For the developed stability indicating method, the ICH Q2 (R1) guidelines were used for validation. Stress degradation studies like hydrolysis under different pH conditions, photolytic degradation, thermal degradation and oxidative degradation as per ICH Q1A (R2) and Q1B guidelines were performed. LC-MS analysis was carried out for the standard everolimus and its alkaline degradation sample using TOF analyser and the degradation pathway was proposed for each degradation product.

Results: The Rf value of everolimus was found to be 0.63±0.03. The response was quite linear over the concentration range of 100-500 ng/band, with the regression coefficient value of 0.9921. Under alkaline hydrolytic conditions, everolimus was analyzed using Liquid Chromatography-Mass Spectrometry (LC-MS). The Retention Time (RT) and prominent mass fragmentation (m/z) for the everolimus standard were observed at 9.46 min with m/z values of 980.56 and 908.54. For the degradation products, DP-1 showed an RT of 8.88 min with m/z values of 349.23, 403.24, 574.33, and 646.35, while DP-2 exhibited an RT of 9.10 min with m/z values of 926.55, 614.32, and 542.30. These data were used to propose the structures of the degradation products.

Conclusion: The proposed method can conveniently be applied for quantitative analysis of everolimus on routine basis and for stability testing under different stress environments.

Downloads

Download data is not yet available.

References

Joel GH, Lee EL. Goodman and Gilman’s, the pharmacological basis of therapeutics. 10th International ed. New York: McGraw-Hill Publishers, Medical Publishing Division; 2000. p. 717-22.

O’Neil MJ. The merck index: an encyclopedia of chemicals drugs and biological. 14th ed. Vol. 40. Whitehouse Station, NJ: Merck and Company Inc; 2006. p. 240.

Renuka D, Nalla Kumar P, Bhagavan Raju M. Method development and validation of everolimus using RP-HPLC. World J Pharm Res. 2019;8(13):949-57.

Bemelman FJ, de Fijter JW, Kers J, Meyer C, Peters Sengers H, de Maar EF. Early conversion to prednisolone everolimus as an alternative weaning regimen associates with beneficial renal transplant histology and function: the randomized-controlled mecano trial. Am J Transplant. 2017;17(4):1020-30. doi: 10.1111/ajt.14048, PMID 27639190.

Budde K, Becker T, Arns W, Sommerer C, Reinke P, Eisenberger U. Everolimus based calcineurin inhibitor free regimen in recipients of de-novo kidney transplants: an open-label randomised controlled trial. Lancet. 2011;377(9768):837-47. doi: 10.1016/S0140-6736(10)62318-5, PMID 21334736.

Kumar A. Comprehensive review on etiopathogenesis treatment and emerging therapies of breast cancer. Asian J Pharm Clin Res. 2021;14(8):20-33. doi: 10.22159/ajpcr.2021.v14i8.41974.

Sharmila D, Rao AL, Kalyani L. Development and validation of stability-indicating high performance liquid chromatographic method for the estimation of everolimus in tablets. Indian J Pharm Sci. 2015;77(5):599-604. doi: 10.4103/0250-474x.169044, PMID 26798176.

Kumari B, Patil PM. Development and validation of stability indicating assay method of everolimus and its marketed formulation. World J Pharm Life Sci. 2021;7(9):86-98.

Boudennaia TY, Napoli KL. Validation of a practical liquid chomatography with ultraviolet detection method for quantification of whole blood everolimus in a clinical TDM laboratory. Ther Drug Monit. 2005;27(2):171-7. doi: 10.1097/01.ftd.0000152681.13647.85, PMID 15795648.

Knapen LM, Beer Y, Bruggemann RJ, Stolk LM, Vries F, Tjan Heijnen VC. Development and validation of an analytical method using UPLC-MS/MS to quantify everolimus in dried blood spots in the oncology setting. J Pharm Biomed Anal. 2018;149:106-13. doi: 10.1016/j.jpba.2017.10.039, PMID 29112898.

Prasad SS, Krishna Mohan GV, Naga Babu A. Development of simple and robust RP-HPLC method for determination of everolimus and its impurities in oral solid dosage form. Asian J Chem. 2019;31(5):1002-8. doi: 10.14233/ajchem.2019.21723.

Pape L, Offner G, Kreuzer M, Froede K, Drube J, Kanzelmeyer N. De novo therapy with everolimus low dose ciclosporine a basiliximab and steroid elimination in pediatric kidney transplantation. Am J Transplant. 2010;10(10):2349-54. doi: 10.1111/j.1600-6143.2010.03266.x, PMID 20840473.

ICH. International Conference on Harmonization. Stability testing of new drug substances and products. Geneva; 2003. p. Q1A (R2).

ICH. Stability testing: photostability testing of new drug substances and products. In: Proceeding of the International Conference on Harmonization. Geneva; 1996. p. Q1(B).

International Conference on Harmonization. Guideline on validation of analytical procedures text and methodology; 2005. p. Q2(R1).

Ferenczi Fodor K, Renger B, Vegh Z. The frustrated reviewer-recurrent failures in manuscripts describing validation of quantitative TLC/HPTLC procedures for analysis of pharmaceuticals. J Planar Chromatogr Mod TLC. 2010;23(3):173-9. doi: 10.1556/JPC.23.2010.3.1.